Description du projet
Une solution de visualisation chirurgicale fait la lumière sur le cancer du cerveau
La chirurgie est le plus souvent utilisée pour retirer les tumeurs cancéreuses. Le principal produit de FluoGuide, à savoir FG001, est injecté dans les veines du patient avant l’opération. Il contient un fluorophore qui se lie aux cellules cancéreuses exprimant le récepteur uPAR (fortement exprimé dans quasiment tous les cancers humains). FG001, propriété de FluoGuide, va révolutionner la chirurgie du cancer en améliorant les résultats chirurgicaux pour plus de 3 millions de patients souffrant d’un cancer traités chaque année. Le glioblastome multiforme (GBM) est le type de cancer le plus agressif qui débute dans le cerveau, avec un très mauvais pronostic. La chirurgie est actuellement extrêmement complexe car l’ablation d’une trop grande quantité de tissu cérébral peut gravement handicaper le patient. Le projet INSTAGLOW, financé par l’UE, se concentrera sur l’accélération du développement de FG001 pour le GBM, améliorant considérablement les procédures chirurgicales pour ces patients.
Objectif
Surgery is a cornerstone in treatment of early cancer, used in 45% of all patients, although cancer commonly recurs after surgery due to incomplete removal. The residual tumour not only leads to avoidable suffering and even dying of patients but also presents a huge financial burden for the healthcare system. As such, there is a major unmet need to accurately delineate tumour from healthy tissue, identify local metastases, and aid surgeons to precisely remove the entire tumour. FluoGuide will deliver FG001, a breakthrough, real-time, surgical visualisation solution that lights up cancer and improve surgical precision during removal surgery. FG001 is the first active targeting fluorescent tumour marker that targets uPAR, a receptor extensively expressed (95%) in a wide range (>50%) of solid tumours such as brain (glioblastoma; GBM), breast, colorectal, lung and head and neck cancers. FluoGuide’s proprietary FG001 will revolutionise cancer surgery to improve the surgical outcome of >3 million cancer patients undergoing surgery every year.
To realise this huge potential, FluoGuide is working on accelerating the development of FG001. Our initial focus is on GBM for which the prognosis is extremely poor with half of all patients dying within 14 months. Moreover, surgery is extremely challenging as removing too much brain tissue can severely disable the patient. FG001 can thus enormously improve surgery of GBM patients. The funding from EIC accelerator pilot will accelerate FG001’s clinical phase IIb/III study for GBM, and catapult FluoGuide to become a leader in cancer surgery guidance. We will generate revenues by 1) direct sales for compassionate use sales (2021) to showcase FG001, 2) direct sales in EU (2023), paid for via reimbursement by insurance companies and governments, and 3) roll-out to US and Asia (2025) through deals with large regional medical companies for local regulatory approval, and marketing and sales to ensure its full economic potential.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
2200 Copenhagen
Danemark
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.